Latest Articles

  • Reducing the risk of breast cancer
    Holly J. Pederson, MD, Zahraa Al-Hilli, MD and Allison W. Kurian, MD
    Cleveland Clinic Journal of Medicine November 2022, 89 (11) 643-652; DOI: https://doi.org/10.3949/ccjm.89a.21113

    Breast cancer remains the most common malignancy in US women. Reducing this burden involves identification of high-risk individuals and personalized risk management.

  • Spontaneous oral hematoma diagnosed as angina bullosa hemorrhagica
    Takeshi Onda, DDS, PhD, Kamichika Hayashi, DDS, PhD, Akira Katakura, DDS, PhD and Masayuki Takano, DDS, PhD
    Cleveland Clinic Journal of Medicine November 2022, 89 (11) 615-616; DOI: https://doi.org/10.3949/ccjm.89a.22040

    The lesions occur on the soft palate, buccal mucosa, and tongue, and only rarely on the masticatory mucosa such as the gingiva and hard palate.

  • When should antithrombotic therapy be resumed after gastrointestinal bleeding?
    Dushyant Singh Dahiya, MD, Asim Kichloo, MD, FACP, Rawan Amir, MD and Farah Wani, MD
    Cleveland Clinic Journal of Medicine November 2022, 89 (11) 630-633; DOI: https://doi.org/10.3949/ccjm.89a.20189

    The timing should be individualized after considering factors related to the bleeding event, thromboembolic risk, and patient comorbidities.

  • Geriatric update 2022: Preventing Alzheimer disease and more
    Melissa Morgan-Gouveia, MD, Kathleen Drago, MD, FACP, Patricia Harris, MD, MS and Meera Sheffrin, MD, MAS
    Cleveland Clinic Journal of Medicine November 2022, 89 (11) 617-624; DOI: https://doi.org/10.3949/ccjm.89a.21094

    Key topics include Alzheimer dementia, effects of frailty and social isolation, COVID-19 risks in patients with dementia, hospital-at-home programs, deprescribing antihypertensive drugs, bisphosphonate-related fractures, and cannabis use.

  • How do I interpret and use quantitative buprenorphine and norbuprenorphine urine levels?
    Richard C. Waters, MD, MSc and Matthew Perez, MD
    Cleveland Clinic Journal of Medicine October 2022, 89 (10) 557-560; DOI: https://doi.org/10.3949/ccjm.89a.21019

    Confirmatory testing of urine samples can be useful in outpatient settings where buprenorphine dosing is not directly observed. But retaining and engaging the patient in effective treatment should be the ultimate goals of testing.

  • How do we maximize diuresis in acute decompensated heart failure?
    Saeid Mirzai, DO, Christopher N. Kanaan, MD, Felix Berglund, MD, Maria Mountis, DO and Heba Wassif, MD, MPH
    Cleveland Clinic Journal of Medicine October 2022, 89 (10) 561-565; DOI: https://doi.org/10.3949/ccjm.89a.22016

    The initial goal is to maximize loop diuretic therapy using urine output or urinary sodium for guidance. Combination therapy can be used when patients respond poorly to escalating loop diuretic doses.

  • Blue sclera: An overlooked finding of iron deficiency
    Yasuhiro Kano, MD
    Cleveland Clinic Journal of Medicine October 2022, 89 (10) 549-550; DOI: https://doi.org/10.3949/ccjm.89a.22045

    The pathogenesis is thought to involve thinning of collagen fibers of the sclera due to iron deficiency, allowing the bluish color of the underlying uvea to become visible.

  • Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidance
    Glenn T. Werneburg, MD, PhD and Daniel D. Rhoads, MD
    Cleveland Clinic Journal of Medicine October 2022, 89 (10) 581-587; DOI: https://doi.org/10.3949/ccjm.89a.22008

    New guidance on ordering, processing, and reporting urine cultures focuses on reducing unnecessary antibiotic use and the misdiagnosis of urinary tract infection.

  • A 65-year-old man with melena and a blood disorder
    Monia E. Werlang, MD, Marilia L. Montenegro, MD and Bhaumik Brahmbhatt, MD, MBBS
    Cleveland Clinic Journal of Medicine October 2022, 89 (10) 573-578; DOI: https://doi.org/10.3949/ccjm.89a.20175

    The patient had chronic anemia related to primary myelofibrosis and was being treated with epoetin alfa and ruxolitinib, with blood transfusions every other week.

  • The role of GLP-1 receptor agonists in managing type 2 diabetes
    Cleveland Clinic Journal of Medicine October 2022, 89 (10) 597;

    The following article in the August 2022 issue contained an error: Nachawi N, Rao PP, Makin V. The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleve Clin J Med 2022; 89(8): 457–464. doi:10.3949/ccjm.89a.21110

Pages